Geneva seeks six-month exclusivity on ranitidine form 1; Novopharm expects marketing plans to proceed.
Executive Summary
GENEVA SEEKING 180-DAY EXCLUSIVITY FOR FORM 1 RANITIDINE in a citizen petition submitted to FDA May 21. In the petition, Geneva asks FDA to confirm that Geneva is considered the first to submit a form 1 ranitidine ANDA containing a "Paragraph IV" certification, which would give Geneva six-month marketing exclusivity for the generic. Geneva's ranitidine ANDA was submitted in January 1994 and tentatively approved in January 1996.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth